Shuttle Pharmaceuticals Announces Private Placement of $4.3 Million of Senior Secured Convertible Note and Warrants

by B2i | Jan 12, 2023 | Press Releases

ROCKVILLE, Md., Jan. 12, 2023 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT) while reducing side...

Shuttle Pharmaceuticals Manuscript Published in Clinical Cancer Research

by B2i | Jan 10, 2023 | Press Releases

ROCKVILLE, Md., Jan. 10, 2023 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced...

Shuttle Pharmaceuticals Manuscript Published in Cancer Research Communications

by B2i | Dec 6, 2022 | Press Releases

ROCKVILLE, Md., Dec. 6, 2022 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced the...

Shuttle Pharmaceuticals Provides Third Quarter 2022 Corporate Update

by B2i | Nov 15, 2022 | Press Releases

ROCKVILLE, Md., Nov. 15, 2022 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today provided a...

Shuttle Pharmaceuticals Engages Theradex Oncology in Preparation for Clinical Study

by B2i | Nov 3, 2022 | Press Releases

ROCKVILLE, Md., Nov. 3, 2022 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT) while reducing its...